Table 2.
Parameters characterizing the efficacy of the applied therapy. (A) Study I: Investigation of KB tumor-bearing CD1 nude mice. (B) Study II: Investigation of PC-3 PIP tumor-bearing BALB/c nude mice.
| Study I: KB Tumor Mouse Model | |||||||
| Group | Tumor Dose (Gy) | First Mouse Euthanized (Day) | Last Mouse Euthanized (Day) | Median Survival (days) | Average Survival (days) | TGDI2 | TGDI5 |
| A: Saline | - | 16 | 36 | 30 | 27 ± 9 (n = 13) |
1.0 ± 0.4 (n = 13) |
1.0 ± 0.3 (n = 13) |
| B: PT | 15 | 42 | 64 (study end) | not reached |
n = 3 (endpoint) 1 n = 8 (alive) 2 |
3.5 ± 1.1 (n = 11) |
2.7 ± 0.7 (n = 9) |
| C: TRT | ~15 | 30 | 64 (study end) | not reached |
n = 3 (endpoint) 1 n = 8 (alive) 2 |
3.2 ± 1.1 (n = 10) |
2.4 ± 0.9 (n = 10) |
| D: PT & TRT | 7.5 + ~7.5 | none | 64 (study end) | not reached |
n = 0 (endpoint) 1 n = 11 (alive) 2 |
4.2 ± 0.6 (n = 11) |
3.2 ± 0.2 (n = 11) |
| Study II: PC-3 PIP Tumor Mouse Model | |||||||
| Group | Tumor Dose (Gy) | First Mouse Euthanized (Day) | Last Mouse Euthanized (Day) | Median Survival (days) | Average Survival (days) | TGDI2 | TGDI5 |
| A: Saline | - | 14 | 34 | 24 | 26 ± 6 (n = 11) |
1.0 ± 0.5 (n = 11) |
1.0 ± 0.4 (n = 10) |
| B: PT | 10 | 26 | 64 (study end) | 42 |
n = 10 (endpoint) 1 n = 1 (alive) 2 |
3.3 ± 1.5 (n = 11) |
2.3 ± 0.4 (n = 8) |
| C: TRT | ~10 | 26 | 64 (study end) | 50 |
n = 8 (endpoint) 1 n = 3 (alive) 2 |
3.8 ± 2.1 (n = 9) |
1.7 ± 0.6 (n = 6) |
| D: PT & TRT | 5.0 + ~5.0 | 32 | 64 (study end) | 42 |
n = 10 (endpoint) 1 n = 1 (alive) |
3.6 ± 1.3 (n = 11) |
2.1 ± 0.6 (n = 11) |
1 Mice that have reached an endpoint; 2 Mice that were still alive at the end of the study.